C4 Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
C4 Therapeutics R&D Spending Growth & History (CCCC)
C4 Therapeutics's r&d spending was $104.2M for fiscal 2025.
View full C4 Therapeutics company overviewC4 Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $104.2M | −$6.4M | −5.78% |
| 2024 | 2024-12-31 | $110.6M | −$7.1M | −6.01% |
| 2023 | 2023-12-31 | $117.7M | −$135,000 | −0.11% |
| 2022 | 2022-12-31 | $117.8M | $23.2M | +24.48% |
| 2021 | 2021-12-31 | $94.7M | $16.2M | +20.68% |
| 2020 | 2020-12-31 | $78.4M | $30.4M | +63.22% |
| 2019 | 2019-12-31 | $48.1M | — | — |
C4 Therapeutics quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $24.5M | −$1.7M | −6.59% |
| Q1 2026 | 2026-03-31 | $24.6M | −$2.5M | −9.11% |
| Q4 2025 | 2025-12-31 | $25.0M | −$7.5M | −23.16% |
| Q3 2025 | 2025-09-30 | $26.0M | −$5.8M | −18.37% |
| Q2 2025 | 2025-06-30 | $26.2M | $2.4M | +10.29% |
| Q1 2025 | 2025-03-31 | $27.1M | $4.5M | +20.14% |
| Q4 2024 | 2024-12-31 | $32.5M | $2.1M | +6.98% |
| Q3 2024 | 2024-09-30 | $31.8M | $3.5M | +12.32% |
| Q2 2024 | 2024-06-30 | $23.8M | −$6.2M | −20.63% |
| Q1 2024 | 2024-03-31 | $22.5M | −$6.5M | −22.41% |
| Q4 2023 | 2023-12-31 | $30.4M | −$261,000 | −0.85% |
| Q3 2023 | 2023-09-30 | $28.3M | −$1.3M | −4.44% |
| Q2 2023 | 2023-06-30 | $29.9M | −$1.4M | −4.46% |
| Q1 2023 | 2023-03-31 | $29.0M | $2.8M | +10.83% |
| Q4 2022 | 2022-12-31 | $30.7M | $4.1M | +15.45% |
| Q3 2022 | 2022-09-30 | $29.7M | $5.4M | +22.06% |
| Q2 2022 | 2022-06-30 | $31.3M | $8.0M | +34.51% |
| Q1 2022 | 2022-03-31 | $26.2M | $5.7M | +27.66% |
| Q4 2021 | 2021-12-31 | $26.6M | $6.1M | +29.94% |
| Q3 2021 | 2021-09-30 | $24.3M | $367,000 | +1.53% |
| Q2 2021 | 2021-06-30 | $23.3M | $5.5M | +31.11% |
| Q1 2021 | 2021-03-31 | $20.5M | $4.2M | +25.83% |
| Q4 2020 | 2020-12-31 | $20.4M | — | — |
| Q3 2020 | 2020-09-30 | $23.9M | $11.0M | +84.85% |
| Q2 2020 | 2020-06-30 | $17.8M | — | — |
| Q1 2020 | 2020-03-31 | $16.3M | — | — |
| Q3 2019 | 2019-09-30 | $12.9M | — | — |
C4 Therapeutics r&d spending trends
Over the last five fiscal years, C4 Therapeutics's r&d spending increased from $78.4M to $104.2M, a change of $25.8M. The latest reported quarter, Q2 2026, shows $24.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review C4 Therapeutics source filings ↗